Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Betamab ApS
APS
In liquidation
Advertising protection
CVR 40337326
Hørsholmvej 11, 3050
Humlebæk
Forskning og eksperimentel udvikling indenfor bioteknologi
·
NACE 721100
Est. 2019 · 7 years old
2 employees
Monitor
Share
Denmark
/
Companies
/
Forskning og eksperimentel udvikling indenfor bioteknologi
/
Betamab ApS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
0M
0M
1M
1M
1M
0M
2019
-1M
2020
EBITDA
DKK millions
0M
-1M
-1M
-2M
-3M
0M
2019
-2M
-200%
2020
Income statement
DKK thousands
Item
2019
2020
Gross profit
-343
-736
Staff expenses
-0
-1.008
EBITDA
-343
-1.744
Depreciation & amort.
-0
-0
EBIT
-343
-1.744
Net financials
-1
-4
Profit before tax
-344
-1.748
Tax
-76
-385
Net profit
-268
-1.364
Balance sheet
DKK thousands
Item
2019
2020
Total assets
211
741
Equity
-217
419
Long-term debt
0
11
Short-term debt
428
312
Total debt
428
322
Financial ratios
5-year trend
EBITDA margin (of gross profit)
-174440100.0%
This company
2019
2020
Equity ratio
56.5%
This company
38.2%
Market median
+48% vs market
2019
2020
Return on equity
-325.5%
This company
18.4%
Market median
-1869% vs market
2019
2020
Net profit margin (of gross profit)
-136369000.0%
This company
2019
2020
Asset turnover (of gross profit)
-0.99×
This company
2019
2020
Debt / equity
0.77×
This company
0.62×
Market median
+24% vs market
2019
2020
Annual reports & filings
Annual report 2020
Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
View
PDF
Annual report 2019
Filed via CVR / Virk · Period 2019-03-11 – 2019-12-31
View
PDF
More on Betamab ApS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
